Saudi Journal of Gastroenterology
Home About us Instructions Submission Subscribe Advertise Contact Login    Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
Users Online: 27 


 
Table of Contents   
ORIGINAL ARTICLE  
Year : 2011  |  Volume : 17  |  Issue : 4  |  Page : 256-260
Prevalence of α-1-Antitrypsin gene mutations in Saudi Arabia


1 Department of Medicine, Gastroenterology Division, Qassim University, Saudi Arabia
2 Research Center, Qassim University, Saudi Arabia
3 Research Center, Qassim University; Department of Pediatrics, College of Medicine, Qassim University, Saudi Arabia

Click here for correspondence address and email

Date of Submission15-Aug-2010
Date of Acceptance17-Nov-2010
Date of Web Publication30-Jul-2011
 

   Abstract 

Background/Aim: α-1 antitrypsin (AAT) deficiency results from mutations of the protease inhibitor (PI). The AAT gene is mapped on chromosome 14 and has been associated with chronic liver disease and chronic obstructive pulmonary disease (COPD). Objective: To determine the frequency of AAT mutations on S and Z carrier alleles in healthy Saudi individuals from Qassim Province in Saudi Arabia. Patients and Methods : A total of 158 healthy, unrelated participants from Qassim Province were recruited. They were genotyped for the two AAT-deficiency alleles, PI*S and PI*Z, using polymerase chain reaction, with primers designed throughout to mediate site-directed mutagenesis. Results: Of the 158 subjects, 11.39% were carriers for the S mutation (i.e., had the MS genotype), whereas 2.53% were carriers for the Z mutation (i.e., had the MZ genotype). The SZ genotype was present in 3.8% of subjects, while the homozygous genotype SS was present in 1.9% of subjects. No subjects showed the ZZ mutant genotype. Accordingly, frequency of the mutant S and Z alleles of AAT gene was 9.49% and 3.19%, respectively. Conclusion: The results obtained showed a high prevalence of the AAT deficiency allele in the Saudi population. This probably warrants adoption of a screening program for at-risk individuals, so that they might initiate adequate prophylactic measures.

Keywords: α-1 antitrypsin, Saudi Arabia, S allele, Z allele

How to cite this article:
Aljarallah B, Ali A, Dowaidar M, Settin A. Prevalence of α-1-Antitrypsin gene mutations in Saudi Arabia. Saudi J Gastroenterol 2011;17:256-60

How to cite this URL:
Aljarallah B, Ali A, Dowaidar M, Settin A. Prevalence of α-1-Antitrypsin gene mutations in Saudi Arabia. Saudi J Gastroenterol [serial online] 2011 [cited 2019 Nov 21];17:256-60. Available from: http://www.saudijgastro.com/text.asp?2011/17/4/256/82580


α-1 antitrypsin (AAT) deficiency is one of the most common serious and potentially fatal hereditary disorders in the adult population. For the most part, AAT deficiency is characterized by clinical manifestations such as respiratory tract diseases and cirrhosis of the liver. [1] It affects all major racial subgroups, with an estimated 120.5 million affected individuals and carriers in the 58 countries surveyed worldwide. In addition, the prevalence of AAT deficiency varies markedly from one country to the other, as well as from one region to the other within a given country. [2]

AAT is a 52-kD glycoprotein comprising a single chain of 394 amino acid residues and three asparagine-linked complex-carbohydrate side chains. [3] In addition to its ability to inhibit trypsin, [4] AAT can also inhibit most neutrophilic serine proteases. Its specific target, however, is neutrophil elastase, an enzyme that digests elastin, basement membrane, and other extracellular matrix components. Indeed, AAT is produced mainly by hepatocytes and secreted into the plasma; it diffuses passively into all of the body organs to protect extracellular tissue structures against a neutrophil elastaseattack [5] (which can cause alveolar parenchyma and support-matrix damage in the lungs). [6]

AAT deficiency is an autosomal-recessive metabolic disease that results from mutations on the protease inhibitor (PI) locus, with encoded gene 14q31-32.3. [7] The polymorphism described on this gene gives rise to protein variants. The gene is organized into three noncoding exons (Ia, Ib, and Ic) and four coding exons (II, III, IV, and V) through sixintrons. [8] The open reading frame is located in the last four exons and codes for 418 amino acids. The first 24 amino acids form a signal peptide, which is cleaved during intracellular processing, resulting in a 394 amino acid-long mature protein. [9],[10]

The normal gene is designated PI*M and is highly pleomorphic, with more than 100 normal and deficiency alleles having been identified using assays based on isoelectric focusing. [11],[12] Most investigators have reported that the two most frequent mutations on the PI locus are PI*S (Glu264Val), which expresses approximately 50 to 60% of AAT, and PI*Z (Glu342Lys), which expresses approximately 10 to 20% of AAT, compared with M-phenotype subjects. [13],[14] These two mutations have different geographic distributions, with PI*S reaching the highest frequencies in the Iberia Peninsula and PI*Z reaching the highest frequencies in northern Europe. PI*ZZ, PI*SZ, and PI*SS are considered to be deficiency genotypes and both PI*MS and PI*MZ are carriers of the anomaly. However, PI*ZZ individuals are at higher risk for chronic obstructive pulmonary disease (COPD) than PI*SZ subjects. [15]

This work aims to determine the frequency of potentially harmful deficiency alleles in the AAT gene among healthy Saudi individuals.


   Patients and Methods Top


Recruitment of individuals

The study population was recruited from primary care clinics within Qassim University's medical centre. The sample comprised students and employees who visited the center for a routine checkup. Informed consent was obtained from all individuals. Ethics approval was obtained from the scientific and ethical committees of Qassim University College of Medicine.

Sampling techniques

For all blood samples, genomic deoxyribonucleic acid(DNA) was extracted from 1 ml of peripheral blood using the MagNA Pure LV blood reagent set (Roche Diagnostics) according to the manufacturer's instruction. DNA from each sample was subjected to polymerase chain reaction (PCR) using a genotyping kit to detect the S and Z alleles.

Each sample underwent PCR involving two different sets of amplification primers-the first being complementary to the normal sequence at the Pi*Z or the Pi*S locus (stock primer mix A) and the second being complementary to the Z or S mutant genotype sequence at the Pi*Z or Pi*S locus (stock primer mix B)-derived from the known sequences. [16] The specific primers successfully identified the S and Z alleles in each case, and were used in optimal PCR conditions [Table 1]. The final 50 μl volume of PCR reactant contained 25 μl of PCR master mix, 1 μl of primer 1 (0.1 μM), 1 μl of primer 2 (0.1 μM), template DNA (10 5 to 10 6 copies), and 23 μl sterile double-distilled H 2 O. The amplification procedure consisted of a time delay enzyme activation step of 20 minutes at 94 o C, followed by 32 cycles,eachone composedof 2 minutes at 94 o C (denaturation), 1 minute at 62 o C (annealing), and 1 minute at 72 o C (extension); there was a final extension step of 10 minutes at 72 o C.
Table 1: The complete stable and destabilized primer panel

Click here to view


Gel electrophoresis

Separation and determination of the products of the PCR was achieved by agarose gel electrophoresis. Each sample pair was run in adjacent lanes; this resulted in a characteristic pattern of bands that was unique to a genotype (i.e., Pi*M, Pi *MZ, Pi*MS, Pi*SS, Pi*SZ, or Pi*ZZ), thus enabling the genotype of each sample to be determined. Using horizontal submarine gels with combs suspended 1 mm above, the gel trays were prepared using 100 ml of Tris/Borate/Ethylenediaminetetraacetic-acid(TBE) buffer solutioncontaining 2% agarose. As the running buffer, TBEcontaining 0.1 mg/mlSYBR green and 0.1% bromophenol blue was used. Electrophoresis was then carried out at 5 V/cm -1 until the dye front had migrated 4 cm toward the anode. After electrophoresis, the gels were placed on an ultraviolet transilluminator at 260 nm and photographed.


   Results Top


We obtained blood samples from 158 healthy, unrelated individuals of Saudi Arab ethnicity. Their ages ranged from 12 to 60 years, with a mean age of 24.52 years. The sample included 105 (66.5%) males and 53 (33.5%) females; 11.39% of sampled subjects were carriers for the S mutation (i.e., had the MS genotype),whereas2.53% were carriers for the Z mutation (i.e., had the MZ genotype). The SZ genotype was present in 3.8% of subjects, while the homozygous genotype SS was present in 1.9% of subjects. No one showed the ZZ mutant genotype. Frequency of the mutant S allele of the AAT gene was 9.49%, while that of the Z allele was 3.19%. These results are summarized in [Table 2].
Table 2: Frequency of AAT genotypes and alleles in the study population: N= 158

Click here to view



   Discussion Top


Since the first report of AAT deficiency in Saudi Arabia in 1979, [17] there has been an increased interest in screening more Saudi individuals to estimate the prevalence of this genetic mutation. The last report of the National Institute of Environmental Health Sciences on the prevalence of AAT deficiency in Saudi Arabia called for the results to be both confirmed and extended to other geographic regions of Saudi Arabia. [18] The present study describes for the first time the prevalence of the two most common AAT deficiency alleles, PI*S and PI*Z, in the Saudi population of Qassim Province, and shows the relatively high frequency of both mutations. Interestingly, allele frequencies of the mutant S allele and the mutant Z allele of the AAT gene were 9.49% and 3.19%, respectively, which is slightly higher than their frequencies in a previous report from a central area of Saudi Arabia (5.2% and 2.2%, respectively). [19] The difference is understandable because current study use more accurate technique to identify the abnormal allies.

Our cohort's S-allele frequency was fairly comparable with the frequencies of surrounding populations from Mediterranean areas and African countries: Egypt, 7.2% [20] ; Portugal, 9.44% [21] ; France, 6.98% [2] ; Spain, 11.16% [22] ; Angola,18.8% [23] ; Namibia, 14.7% [23] ; Nigeria, 6.4% [23] ; and Botswana, 4.5% [23] . However, our cohort's S-allele frequency was higher than those reported in other countries of the world: Tunisia, 0.6% [24] ; Jordan, 0.83%, Malaysia, 2.41%, Thailand, 2.26%, and South Korea, 3.1%. [2]

Similarly, the frequency of the PI*Z mutant allele in our cohort (3.19%) was fairly comparable with European countries such as Denmark (2.26%), Estonia (2.45%), Poland (2.45%), Sweden (2.3%), and New Zealand (2.57%), but lower than the frequency in Latvia (4.09%). [2] However, the frequency of the PI*Z mutant allele in our cohort was much higher than the frequency in Jordan (0.00%), Malaysia (0.1%), Thailand (1.32%), and South Korea (0.61%). These comparisons are summarized in [Table 3]. [2],[17],[18],[19],[25]
Table 3: Allele frequencies of Pi M, PI S and PI Z in Saudi population compared withother populations[2],[17],[18],[19],[25]

Click here to view


It was previously reported that the levels of AAT in the blood of Saudi individuals is 95 to 275 mg/dl for adult males and 100 to 350 mg/dl for adult females. [26] In a recent study comparing the international prevalence of AAT mutations, in which patients were pooled from multiple studies conducted in Saudi Arabia (for an estimatedtotal of 801 screened Saudi patients), it was concluded that the total calculated prevalence of PI*S and PI*Z alleles is 11.3% for this population. [18]

It has been documented in nationwide prospective screening studies that only 10 to 15% of the Pi*ZZ population develop clinically significant liver disease in the first 20 years of life; however, 85 to 90% of these individuals have elevated serum transaminases in infancy without any obvious liver injury by the age of 18 years, while patients heterozygous for the Pi*Z allele still bear an increased risk for chronic liver disease. [27],[28] Also, it was demonstrated that hepatic dysfunction could develop at as early as 6 months of age among MS-allele heterozygotes, with subsequent development of cryptogenic cirrhosis between the ages of 1 month and 18 years. [29]

Several studies indicate that AAT deficiency is far less familiar to many clinicians than its prevalence would suggest. [30] Unrecognized individuals with severe AAT deficiency are usually the result of the following two reasons. The first is masked normal phenotype expression despite severe deficiency and the second is undiagnosed cases despite suggestive symptoms. [25],[31],[32] The relative proportion of these two groups remains unknown. It was estimated that the average delay between onset of symptoms and diagnosis of AAT deficiency is about 7.2 years. Furthermore, recent studies indicate that under-recognition persists, despite extensive educational efforts and the publication of evidence-based guidelines for diagnosis and management of AAT deficiency. [5],[30],[31]

Current study should encourage practicing physicians in Saudi Arabia to adhere to published guidelines by routinely screening symptomatic adults with emphysema, COPD,asthma, or unexplained liver disease. AdvancedAAT patients might be candidate of AAT replacement therapy, while AAT carrier diagnosis might provide genetic counseling to persons who are planning a pregnancy or are in the prenatal period. In addition, awareness of carrying a gene that may increase the susceptibility to COPD may be an additional factor for a successful enrollment of patients in smoking cessation program. [33]


   Conclusion Top


The results obtained from this study, which show the relatively high frequency for S and Z allele mutations leading to AAT deficiency and subsequent potential risks of liver dysfunction and COPD, [34],[35],[36],[37],[38],[39],[40],[41],[42] probably warrant the adoption of screening measures for genetically susceptible groups. However, we recommend that further studies of the Saudi population be carried out, especially to address the effects of genetic background (represented by such potentially harmful gene mutations), together with other environmental factors on the incidence and prevalence of hepatic and pulmonary disorders.

 
   References Top

1.Lomas DA, Parfrey H. Alpha 1 Antitrypsin deficiency 4: Molecular pathophysiology. Thorax 2004;59:529-35.  Back to cited text no. 1
    
2.De Serres FJ. Worldwide racial and ethnic distribution of alpha-1-antitrypsin deficiency: Details of an analysis of published genetic epidemiological surveys. Chest 2002;122:1818-29.  Back to cited text no. 2
    
3.Brantly ML, Paul LD, Miller BH, Falk RT, Wu M, Crystal RG. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis 1988;138:327-36.  Back to cited text no. 3
    
4.Neto L, Junior C, Cardoso G, Ferreira A, Marino G, Monteiro N. Pulmonary aspects in alpha-1-antitrypsin deficiency. Rev Port Pneumol 2004;10:145-54.  Back to cited text no. 4
    
5.American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003;168:818-55.  Back to cited text no. 5
    
6.Stockley RA. Alpha (1)-antitrypsin: More than just deficiency. Thorax 2004;59:363-4.  Back to cited text no. 6
    
7.DeMeo DL,Silverman EK. A1-Antitrypsin deficiency. 2: Genetic aspects of alpha(1)-antitrypsin deficiency: Phenotypes and genetic modifiers of emphysema risk. Thorax 2004;59:259-64.  Back to cited text no. 7
    
8.Blank CA, Brantly M. Clinical features and molecular characteristics of alpha 1-antitrypsin deficiency. Ann Allergy 1994;72:105-20.  Back to cited text no. 8
    
9.Long GL, Chandra T, Woo SL, Davie EW, Kurachi K. Complete sequence of the cDNA for human alpha 1-antitrypsin and the gene for the S variant. Biochemistry 1984;23:4828-37.  Back to cited text no. 9
    
10.Perlino E, Cortese R, Ciliberto G. The human alpha-1- antitrypsin gene is transcribed from two different promoters in macrophages and hepatocytes. EMBO J1987;6:2767-71.  Back to cited text no. 10
    
11.Human Genetics Programme, Division of Noncommunicable Diseases. Alpha-1 antitrypsin deficiency. Report of a WHO meeting. Geneva, Switz: World Health Organization; 1996. Available from: http://whqlibdoc.who.int/HQ/1996/WHO_HGN_AATD_WG_96.5.pdf. [Accessed 2010 Aug 11].  Back to cited text no. 11
    
12.Alpha 1-Pi deficiency. World Health Organization [article in German].Pneumologie 1997;51:885-918.  Back to cited text no. 12
    
13.Stoller JK, Aboussouan LS. Alpha-1-antitrypsin deficiency. Lancet 2005;365:2225-36.  Back to cited text no. 13
    
14.Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency-a model for conformational diseases. N Engl J Med 2002;346:45-53.  Back to cited text no. 14
    
15.Blanco I, de Serres FJ, Fernandez-Bustillo E, Lara B, Miravitlles M. Estimated numbers and prevalence of PIFNx01S and PIFNx01Z alleles of alfa-1-antitrypsin deficiency in European countries. Eur Respir J 2006;27:77-84.  Back to cited text no. 15
    
16.Stockley RA,Campbell EJ. Alpha-1-antitrypsin genotyping with mouthwash specimens. Eur Respir J 2001;17:356-9.  Back to cited text no. 16
    
17.Goedde HW, Benkmann HG, Agarwal DP, Hirth L, Bienzle U, Dietrich M, et al. Genetic studies in Saudi Arabia: red cell enzyme, haemoglobin and serum protein polymorphisms. Am J Phys Anthropol 1979;50:271-7.  Back to cited text no. 17
    
18.De Serres FJ, Blanco I, Fernández-Bustillo E. Estimated numbers and prevalence of PIFNx01S and PIFNx01Z deficiency alleles of alpha1-antitrypsin deficiency in Asia. Eur Respir J 2006;28:1091-9.  Back to cited text no. 18
    
19.Warsy AS, El-Hazmi MA, Sedrani SH, Kinhal M. Alpha-1-antitrypsin phenotypes in Saudi Arabia: A study in the central province. Ann Saudi Med 1991;11:159-62.  Back to cited text no. 19
    
20.Settin A, El-Bendary M, Abo-Al-Kassem R, El BazR. Molecular analysis of A1AT (S and Z) and HFE (C282Y and H63D) gene mutations in Egyptian cases with HCV liver cirrhosis. J Gastrointestin Liver Dis 2006;15:131-5.  Back to cited text no. 20
    
21.Spınola C, Bruges-Armas J, Pereira C, Brehm A, Spınola H. Alpha-1-antitrypsin deficiency in Madeira (Portugal): The highest prevalence in the world. Respir Med 2009;103:1498-502.  Back to cited text no. 21
    
22.De la Roza C, Lara B, Vila S, Miravitlles M. Alpha-1-antitrypsin deficiency: Situation in Spain and development of a screening program. Arch Bronconeumol 2006;42:290-8.  Back to cited text no. 22
    
23.De Serres FJ, Blanco I, Bustillo EF. Pi S and Pi Z alpha-1 antitrypsin deficiency worldwide. A review of existing genetic epidemiological data. Monaldi Arch Chest Dis 2007;67:184-208.  Back to cited text no. 23
    
24.DendenS, Khelil H, Perrin P, Daimi H, Leban N, Ouaja A, et al. Alpha 1 antitrypsin polymorphism in the tunisian population with special reference to pulmonary disease. Pathol Biol 2008;56:106-10.  Back to cited text no. 24
    
25.Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C. Delay in diagnosis of alpha 1-antitrypsin deficiency: A continuing problem. Chest 2005;128:1989-94.  Back to cited text no. 25
    
26.Sedrani SH, el-Hinnawi SI, Warsy AS. Establishment of a normal reference range for alpha 1-antitrypsin in Saudis using rate nephelometry. Am J Med Sci 1988;296:22-6.  Back to cited text no. 26
    
27.Sveger T, Thelin T, McNeil TF. Young adults with alpha 1-antitrypsin deficiency identified neonatally: their health, knowledge about and adaptation to the high risk condition. Acta Pediatr 1997;86:37-40.  Back to cited text no. 27
    
28.Volpert D, Molleston JP, Perlmutter DH. Alpha 1-antitrypsin deficiency-associated liver disease progresses slowly in some children. J Pediatr Gastroenterol Nutr 2000;31:258-63.  Back to cited text no. 28
    
29.Lima LC, Matte U, Leistner S, Bopp AR, Scholl VC, Giugliani R, et al. Molecular analysis of the Pi Z allele in patients with liver disease. Am J Med Genet 2001;287:90-104.  Back to cited text no. 29
    
30.Silverman EK, Miletich JP, Pierce JA, Sherman LA, Endicott SK, Broze GJ Jr, et al. Alpha 1-antitrypsin deficiency: High prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis 1989;140:961-6.  Back to cited text no. 30
    
31.Campos MA, Waner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with alpha 1-antitrypsin deficiency between 1968 and 2003. Chest 2005;128:1179-86.  Back to cited text no. 31
    
32.Stoller JK, Smith P, Yang P, Spray J. Physical and social impact of alpha 1-antitrypsin deficiency: Results of a survey. Cleve Clin J Med 1994;61:461.  Back to cited text no. 32
    
33.Ferrarotti I, Gorrini M, Scabini I, Ottaviani S, Mazzola P, Campo I, et al. Secondary outputs of alpha1-antitrypsin deficiency targeted detection programme. Respir Med 2008;102:354-8.  Back to cited text no. 33
    
34.Ikebe N, Akaike T, Miyamoto Y, Hayashida K, Yoshitake J, Ogawa M, et al. Protective effect of S-nitrosylated alpha(1)-protease inhibitor on hepatic ischemia-reperfusion injury. J Pharmacol Exp Ther 2000;295:904-11.  Back to cited text no. 34
    
35.Perlmutter DH. Alpha 1-antitrypsin deficiency: Liver disease associated with retention of a mutant secretory glycoprotein in the endoplasmic reticulum. Methods Mol Biol 2003;232:39-56.  Back to cited text no. 35
    
36.Perlmutter DH. Liver injury in alpha 1-antitrypsin deficiency: An aggregated protein induces mitochondrial injury. J ClinInvestig 2002;110:1579-83.  Back to cited text no. 36
    
37.Teckman JH, An JK, Blomenkamp K, Schmidt B, Perlmutter D. Mitochondrial autophagy and injury in the liver in alpha 1-antitrypsin deficiency. Am J Physiol Gastrointest Liver Physiol 2004;286:G851-62.  Back to cited text no. 37
    
38.Teckman JH, An JK, Loethen S, Perlmutter DH. Fasting in alpha 1-antitrypsin deficient liver: Constitutive activation of autophagy. Am J Physiol Gastrointest Liver Physiol 2002;283:G1156-65.  Back to cited text no. 38
    
39.Teckman JH, Perlmutter DH. Retention of mutant alpha (1)-antitrypsin Z in endoplasmic reticulum is associated with an autophagic response. Am J Physiol Gastrointest Liver Physiol 2000;279:G961-74.  Back to cited text no. 39
    
40.Aldonyte R, Jansson L, Ljungberg O, Larsson S, Janciauskiene S. Polymerized alpha-antitrypsin is present on lung vascular endothelium. New insights into the biological significance of alpha-antitrypsin polymerisation. Histopathology 2004;45:587-92.  Back to cited text no. 40
    
41.Mulgrew AT, Taggart C, Lawless MW, Green CM, Brantly ML, O′Neill SJ, et al. Z alpha-1-antitrypsin polymerizes in the lung and serves as a neutrophil chemoattractant. Chest 2004;125:1607-9.  Back to cited text no. 41
    
42.Strange C, Stoller JK, Sandhaus RA, Dickson R, Turino G. Results of a survey of patients with alpha-1 antitrypsin deficiency. Respiration 2006;73:185-90.  Back to cited text no. 42
    

Top
Correspondence Address:
Badr Aljarallah
Department of Medicine, King Fahad Specialist Hospital, Faculty of Medicine, Qassim University, Maledia-51452
Saudi Arabia
Login to access the Email id

Source of Support: 1st author received grant from Qassim University, Conflict of Interest: None


DOI: 10.4103/1319-3767.82580

Rights and Permissions



 
 
    Tables

  [Table 1], [Table 2], [Table 3]

This article has been cited by
1 The Challenge of Detecting Alpha-1 Antitrypsin Deficiency
James K. Stoller,Mark Brantly
COPD: Journal of Chronic Obstructive Pulmonary Disease. 2013; 10(S1): 26
[Pubmed] | [DOI]
2 Alpha-1 Antitrypsin Deficiency in Iranian Patients with Chronic Obstructive Pulmonary Disease
Bita Geramizadeh,Zahra Jowkar,Leila Karami,Masoum Masoumpour,Samrad Mehrabi,Mohammad-Ali Ghayoumi
Iranian Red Crescent Medical Journal. 2013; 15(11)
[Pubmed] | [DOI]
3 The challenge of detecting alpha-1 antitrypsin deficiency
Stoller, J.K. and Brantly, M.
COPD: Journal of Chronic Obstructive Pulmonary Disease. 2013; 10(S1): 26-34
[Pubmed]
4 A review of α 1-antitrypsin deficiency
Stoller, J.K. and Aboussouan, L.S.
American Journal of Respiratory and Critical Care Medicine. 2012; 185(3): 246-259
[Pubmed]
5 A Review of a1-Antitrypsin Deficiency
James K. Stoller,Loutfi S. Aboussouan
American Journal of Respiratory and Critical Care Medicine. 2012; 185(3): 246
[Pubmed] | [DOI]



 

Top
  
 
  Search
 
  
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Patients and Methods
   Results
   Discussion
   Conclusion
    References
    Article Tables

 Article Access Statistics
    Viewed2086    
    Printed151    
    Emailed0    
    PDF Downloaded338    
    Comments [Add]    
    Cited by others 5    

Recommend this journal